Development, Optimization and Validation of a Selective Stability Indicating RP-HPLC Method for Estimation of Glecaprevir and Pibrentasvir and Its Degradation Products Using Quality by Design Approach

C. VANITHA^{1,2}, S.V. SATYANARAYANA³ and K. BHASKAR REDDY^{2,*}

¹Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu-515002, India

²Department of Pharmaceutics, Sri Venkateswara College of Pharmacy, Chittoor-517127, India

³Department of Chemical Engineering, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu-515002, India

*Corresponding author: E-mail: bhaskurra@gmail.com

Received: 6 February 2019;

Accepted: 18 March 2019;

Published online: 21 May 2019;

AJC-19410

The present work focused on QbD driven approach for the development, optimization of stability indicating method for glecaprevir and pibrentasvir in bulk drug and its degradation products. The chromatographic separation was performed on Hypersil C₈ (150 mm × 4.6, 5 μ) with a flow rate of 1 mL/min at 260 nm. The mobile phase employed was sodium phosphate monobasic and monohydric buffer and acetonitrile (65:35) having pH of 4.2 at 30 °C of column temperature. The degradation studies were carried out for glecaprevir and pibrentasvir under the stress condition hydrolysis (acid, base and neutral), oxidation, photolytic and thermal as per ICH guidelines. In alkali degradation chromatogram, more number of degradant peaks was appeared along with the risk factor, selectivity of the method. The selectivity of the method was established by resolving the resolution of degradant peaks and retention time of drugs by the application of design of experiment. The interaction effect of factors of pH mobile phase, column temperature and % mobile phase were studied through response surface method (RSM) and central composite design (CCD). The optimized selective method was established for the detection of glecaprevir and pibrentasvir along with degradant peaks by optimized conditions were proposed by the model. Then the optimized method was validated for the parameters like linearity, accuracy, precision and robustness as per ICH guidelines.

Keywords: Central composite design, Glecaprevir, Pibrentasvir, Stress degradation.

INTRODUCTION

Glecaprevir and pibrentasvir are the second generation direct acting antiviral drugs for HCV [1]. The non-structural (NS) protein 3/4A protease inhibitor, glecaprevir (ABT-493) is combined with HCV NS5A inhibitor, pibrentasvir (ABT 530) as fixed dosage form to treat HCV genotypes 1-6. This fixed dose combination has potent antiviral activity against all genotypes of hepatitis C viruses [2]. The proteolysis of HCV polyprotein is essential step for viral replication which is inhibited by glecaprevir. The NS5A is responsible for viral replication and virions assemble of virus which is inhibited by pibrentasvir [2]. In the literature few analytical methods has been reported like RP-HPLC methods [3-5], UPLC [6] method, Stability indicating assay methods [7,8]. The drug combination

were newly introduced for the treatment of HCV, so very few analytical basic methods were reported but till now none have reported on the estimation of glecaprevir and pibrentasvir stability by quality by design approach. The first report of this work will provide the complete profile of targeted drug, risk assessment aspects and comprehensive study of method variables and their interaction effect on response. The QbD approach absolutely overtook the disadvantages of traditional one factor changing method by providing the detailed interaction of multiple variables at a time on method response. It also provides a sound knowledge on understanding of method and product by the interaction and risk assessment [9-13].

Hence an attempt was made to develop simple, sensitive, precise, robust selective stability indicating RP-HPLC method was developed for the estimation of glecaprevir and pibrentasvir

by QbD approach. The objective of study includes forced degradation of drugs as per ICH guidelines, preliminary selection of influencing variables using factorial design, comprehensive study of interaction of variables through statistical approaches, optimization of methods by desirability method and verification of the method followed by validation of method as per ICH guidelines.

EXPERIMENTAL

Distilled water (HPLC grade), acetonitrile (HPLC grade), sodium dihydrogen orthophosphate mono basic, orthophosphoric acid (AR grade) were purchased from Merck specialties private limited, Mumbai, India. The active pharmaceutical ingredient was purchased from MSN pharmaceuticals, Hyderabad.

Liquid chromatography comprised a binary solvent pump and photodiode-array detector used for separation (WATERS 2695) utilizing Empower-2 software for processing (Waters Corporation, Milford, MA, USA).

Design of expert software: The design expert software 11.0.5.0 free trial version was used to plan the experiment's design.

Chromatographic conditions: The chromatographic separation was performed on Hypersil C₈ (150 mm × 4.6, 5 μ) with a flow rate of 1 mL/min at 260 nm. The column temperature was maintained at 30 °C. The mobile phase employed was sodium phosphate monobasic and monohydric buffer and acetonitrile (65:35) having pH of 4.2. The pH of buffer solution was adjusted with 0.1 % orthophosphoric acid.

Stress degradation study: The drugs were treated with 0.1 N HCl for 3 h at 80 °C to perform acid degradation, treated with 0.1 N NaOH for 3 h at 80 °C for base degradation, treated with 20 % & 30 % H₂O₂ for 3 h at 80 °C for peroxide degradation. The standard drug solution was placed in oven at 105 °C for 76 h to study dry heat degradation. Stress testing under neutral conditions was studied by refluxing the drug in water for 75 h at 60 °C.

Before injecting the samples into system, they were neutralized and diluted to get 100 μg/mL of glecaprevir and 40 μg/mL for pibrentasvir.

RESULTS AND DISCUSSION

Defining quality target profile: It is a prospective summary of quality characteristics of a drug product taking into account together with the attributes affecting method performance (Table-1).

Selection of chromatographic conditions: The mobile phase employed was chromatographic separation were sodium phosphate monobasic and monohydric buffer and acetonitrile (65:35) having pH of 4.2 at 1 mL/min flow rate. The column temperature was maintained at 30 °C and detection was carried at 260 nm. Retention time of glecaprevir and pibrentasvir were obtained at 2.638 min and 3.708 (Fig. 1).

Fig. 1. Optimized chromatogram of glecaprevir and pibrentasvir

Forced degradation: Stress degradation studies of glecaprevir and pibrentasvir were carried out under hydrolysis (acid, base and neutral), oxidation, photolytic. The chromatograms of forced degradation studies were shown in Fig. 2. The glecaprevir and pibrentasvir were stable under the stress condition of thermal, UV and water (Table-2). The drug was treated under acidic and Peroxide condition, it shows degradation with one degradant peak in each condition. But in alkali conditions it shows three degradant peaks (DP1, DP2, DP3). The DP1 and DP2 resolution were 2.1, which are more likely to co-elute.

So it is evident that the alkali condition has significant effect on the stability of glecaprevir and pibrentasvir than any other stress condition.

Risk assessment: Actually the degradant peaks formed in alkali degradation were eluted very closely. So the selectivity of the proposed method was affected by co-elution of these degradant peaks and drug peaks. The risk of co-elution was very high which may lead to method failure often encountered in stability indicating method.

Design of experiment: Based on the risk assessment the critical analytical attributes which shows effect on method performance were identified as mobile phase ratio, pH of mobile phase and column temperature. The method responses selected were Retention time of the drug and resolution between degradant peak 1 and degradant peak 2 which likely co-elute and

TABLE-1
QTPP FOR GLECAPREVIR AND PIBRENTASVIR

QTPP element	Target	Justification
Sample		
Dosage form	API and degradation products	Analytical method need to develop to assess the stability of the drug with its degradation products.
Appearance	White to half white	Available in solid form
Impurity percentage	0.09 %	Critical
Method		
Method type	Reverse phase	Used to get good retention time for moderate water soluble drug like glecaprevir (log p 4.26) & pibrentasvir (solubility < 0.1 mg/mL)
Instrument type	Binary pump	For effective mixing of solvent system
Stability indicating assay	API and degradation products	To indicate the stability of product under various stress conditions

TABLE-2
DEGRADATION PERCENTAGE OF GLECAPREVIR AND PIBRENTASVIR UNDER VARIOUS STRESS CONDITION

Condition	Assay initial (%)	Glecaprevir		Pibrentasvir	
		Assay after degradation (%)	Degradation (%)	Assay after degradation (%)	Degradation (%)
Acid	100.00	65.06	34.94	65.13	34.87
Base	100.00	74.39	25.61	88.05	11.95
Peroxide	100.00	76.45	23.55	84.51	15.49
Thermal	100.00	95.46	4.54	96.37	3.63

Fig. 2. Forced degradation chromatograms of glecaprevir and pibrentasvir

lead to method failure often. Preferably in response surface method, 2^3 factorial designs were selected. The selected method responses and its levels were given in Table-3.

TABLE-3
DESIGN OF EXPERIMENTS-LEVELS OF VARIABLES

Variables	Low level -1 level	Mid level 0 level	High level +1 level
Mobile phase ratio (%)	55.00	65.00	75.00
pH mobile phase	3.50	4.2	4.9
Column temperature (°C)	27	30	33

The central composite design was selected and 20 chromatogram runs were conducted as per DoE design and the method responses of each runs were mentioned in Table-4.

Statistical analysis of method responses

ANOVA for method response 1 - resolution: The analysis of variance (ANOVA) of regression parameters of the predicted response surface quadratic model for resolution was obtained from DoE software (Table-5). The Model F-value of 18.13 implies the model is significant. There is only 0.01 % chance that a “Model F-Value” this large could occur due to noise. Values of “Prob > F” less than 0.0500 indicate model terms are significant. In this case A, C, AC, A^2 , B^2 are significant model terms. Values greater than 0.1000 indicate the model terms are not significant. The “Lack of Fit F-value” of 4.91 implies that there is a 5.27 % chance that a “Lack of Fit F-value” this large could occur due to noise. The “Pred R-Squared” of 0.6223 is closed to the “Adj R-Squared” of 0.8903 as one might normally expect. “Adeq Precision” measures the signal to noise ratio. A ratio greater than 4 is desirable. The model ratio of 15.372 indicates an adequate signal. This model can be used to navigate the design space.

The equation in terms of actual factors can be used to make predictions about the response of resolution and process variables by polynomial equation:

$$\begin{aligned} \text{Res} = & -42.70331 + 5.43168 \text{ pH} + 1.87400 \text{ TEM} + 0.044293 \\ & \% \text{ MP} - 0.029762 \text{ pH} * \text{TEM} + 0.058929 \text{ pH} * \% \text{ MP} + \\ & 4.16667\text{E} - 004 \text{ TEM} * \% \text{ MP} - 0.83982 \text{ pH}^2 - \\ & 0.030010 \text{ TEM}^2 - 1.99380\text{E} - 003 \% \text{ MP}^2 \end{aligned}$$

3D and Contour graph for resolution: From ANOVA report on resolution, it is clearly states that interaction effect of pH and temperature has p-value higher than 0.05 so interaction effect these terms doesn't have any significant effect on resolution. The interaction effect temperature and % mobile phase p-value also greater than 0.05 so interaction effect these terms doesn't have any significant effect on resolution.

The interaction effect of pH of mobile phase and % mobile phase ratio has significant effect on resolution. By keeping constant temperature at 30 °C, the interaction effect of pH of mobile phase and % mobile phase ratio were studied from contour and 3D graph. From the graph at lower pH and lower level of % mobile phase can give resolution lesser than 1. At higher pH and higher % mobile phase ratio can give resolution more than 2.8 (Fig. 3).

ANOVA for method response 2 – retention time of glecaprevir: The analysis of variance (ANOVA) of regression parameters of the predicted response surface quadratic model for retention time of glecaprevir was obtained from DoE software and given in Table-6. The Model F-value of 17.06 implies the model is significant. There is only a 0.01 % chance that a “Model F-Value” this large could occur due to noise. Values of “Prob > F” less than 0.0500 indicate model terms are significant. In this case A, C, A^2 , C^2 are significant model

TABLE-4
CENTRAL COMPOSITE DESIGN FOR SCREENING OF METHOD PARAMETERS

Std.	Run	Factor 1 A: pH Mobile Phase	Factor 2 B: Temperature	Factor 3 C: mobile phase ratio	Response 1 Resolution	Response 2 t _R of GLEC	Response 2 t _R of PIBRE
		—	°C	%	Number	Time (min)	Time (min)
4	1		33	55	1.2	2.199	2.683
6	2	4.9	27	75	3.1	2.939	5.204
17	3	4.2	30	65	2.2	2.492	3.511
8	4	4.9	33	75	2.9	2.953	5.342
3	5	3.5	33	55	0	2.04	2.648
16	6	4.2	30	65	2.1	2.492	3.617
14	7	4.2	30	81.81793	2.6	3.569	7.114
15	8	4.2	30	65	2.2	2.487	3.695
1	9	3.5	27	55	0	2.052	2.675
13	10	4.2	30	48.18207	0.9	2.104	2.465
5	11	3.5	27	75	0	2.658	3.955
9	12	3.022745	30	65	0	2.028	3.329
18	13	4.2	30	65	1.7	2.274	3.214
20	14	4.2	30	65	2.2	2.484	3.486
2	15	4.9	27	55	1.5	2.206	2.689
12	16	4.2	35.04538	65	1.4	2.467	3.463
19	17	4.2	30	65	2.2	2.496	3.594
10	18	5.377255	30	65	2.3	2.386	3.414
7	19	3.5	33	75	0	2.312	5.272
11	20	4.2	24.95462	65	1.7	2.512	3.585

TABLE-5
ANOVA FOR QUADRATIC MODEL FOR METHOD RESPONSE 1-RESOLUTION

Source	Sum of squares	df	Mean square	F-value	p-value	
Model	19.29542	9	2.143936	18.12935	< 0.0001	Significant
A-pH	11.56619	1	11.56619	97.80492	< 0.0001	
B-TEM	0.073889	1	0.073889	0.624816	0.4476	
C-%MP	2.777643	1	2.777643	23.48805	0.0007	
AB	0.03125	1	0.03125	0.264253	0.6184	
AC	1.36125	1	1.36125	11.51088	0.0069	
BC	0.00125	1	0.00125	0.01057	0.9201	
A ²	2.440442	1	2.440442	20.63664	0.0011	
B ²	1.051291	1	1.051291	8.889828	0.0138	
C ²	0.572885	1	0.572885	4.844374	0.0524	
Residual	1.182577	10	0.118258			
Lack of Fit	0.982577	5	0.196515	4.912886	0.0527	Not significant
Pure Error	0.2	5	0.04			
Cor Total	20.478	19				
Summary of quadratic model						
Std. Dev.	0.343886	PRESS	7.73367	Adequate precision		15.37228
R ²	0.942251	Adjusted R ²	0.890278	Predicted R ²		0.622342

terms. Values greater than 0.1000 indicate the model terms are not significant. The “Lack of Fit F-value” of 3.07 implies the Lack of Fit is not significant relative to the pure error. There is a 12.18 % chance that a “Lack of Fit F-value” this large could occur due to noise. Non-significant lack of fit is good – we want the model to fit. The “Pred R-Squared” of 0.6191 is as close to the “Adj R-Squared” of 0.8838 as one might normally expect. “Adeq Precision” measures the signal to noise ratio. A ratio greater than 4 is desirable, ratio of 16.270 indicates an adequate signal. This model can be used to navigate the design space.

The equation in terms of actual factors can be used to make predictions about the response of retention time of glecaprevir and process variables by polynomial equation:

$$\begin{aligned} \text{Rt-GLEC} = & + 3.08462 + 0.67368\text{pH} + 0.032872\text{TEM} - \\ & 0.12098 \% \text{ MP} + 0.021726\text{pH} * \text{TEM} + 0.010875\text{pH} * \\ & \% \text{ MP} - 1.30417\text{E}-003\text{TEM} * \% \text{ MP} - 0.21907\text{pH}^2 - \\ & 8.29429\text{E}-004 \text{TEM}^2 + 1.15218\text{E}-003 \% \text{ MP}^2 \end{aligned}$$

3D and Contour graph for retention time of glecaprevir:

From ANOVA report on retention time of glecaprevir, it clearly states that the interaction effect of pH and temperature, temperature and % mobile phase has p-value higher than 0.05 so interaction effect these terms doesn't have any significant effect on retention time of glecaprevir.

The interaction effect of pH of mobile phase and % mobile phase ratio has also very little significant effect on retention time of glecaprevir. By keeping constant temperature at 30 °C, the interaction effect of pH of mobile phase and % mobile

Fig. 3. (a) Contour plots and (b) response surface for resolution as a function of pH of mobile phase and % mobile phase ratio (constant temperature 30 °C)

TABLE-6
ANOVA FOR QUADRATIC MODEL FOR METHOD RESPONSE 2 – RETENTION TIME OF GLECAPREVIR

Source	Sum of squares	df	Mean square	F-value	p-value	
Model	2.440756	9	0.271195	17.0635	< 0.0001	Significant
A-pH	0.247119	1	0.247119	15.54865	0.0028	
B-TEM	0.013331	1	0.013331	0.838767	0.3813	
C-%MP	1.707389	1	1.707389	107.4283	< 0.0001	
AB	0.016653	1	0.016653	1.047809	0.3301	
AC	0.04636	1	0.04636	2.916962	0.1185	
BC	0.012246	1	0.012246	0.770522	0.4007	
A ²	0.166057	1	0.166057	10.44822	0.0090	
B ²	0.000803	1	0.000803	0.050528	0.8267	
C ²	0.191313	1	0.191313	12.03735	0.0060	
Residual	0.158933	10	0.015893			
Lack of Fit	0.119892	5	0.023978	3.07094	0.1218	Not significant
Pure Error	0.039041	5	0.007808			
Cor Total	2.599689	19	0.271195			
Summary of quadratic model						
Std. Dev.	0.13	PRESS	0.99	Adequate precision	16.270	
R ²	0.9389	Adjusted R ²	0.8838	Predicted R ²	0.6191	

phase ratio were studied from contour and 3D graph (Fig. 4). From 65 to 55 % of mobile phase ratio and pH 3.7 to 4.9 gives the retention time less than 2.3 min. at higher level of pH and mobile phase ratio gives the rise in retention time of glecaprevir.

ANOVA for method response 3 – retention time of pibrentasvir: The analysis of variance (ANOVA) of regression parameters of the predicted response surface quadratic model for retention time of pibrentasvir was obtained from DoE software and given in Table-7. The Model F-value of 35.01 implies the model is significant. There is only 0.01 % chance that a “Model F-Value” this large could occur due to noise. Values of “Prob > F” less than 0.0500 indicate model terms are significant. In this case C, C² are significant model terms. Values greater than 0.1000 indicate the model terms are not significant. The “Lack of Fit F-value” of 4.58 implies there is a 6.02 % chance that a “Lack of Fit F-value” this large

could occur due to noise. The “Pred R-Squared” of 0.7892 is in reasonable agreement with the “Adj R-Squared” of 0.9415. “Adeq Precision” measures the signal to noise ratio. A ratio greater than 4 is desirable, ratio of 22.652 indicates an adequate signal. This model can be used to navigate the design space.

The equation in terms of actual factors can be used to make predictions about the response of retention time of pibrentasvir and process variables by polynomial equation.

$$\begin{aligned} \text{Rt-PIB} = & + 16.65814 + 2.04414 \text{ pH} + 0.059328 \text{ TEM} \\ & - 0.71127 \% \text{ MP} - 0.068929 \text{ pH} * \text{ TEM} + 0.022679 \text{ pH} * \\ & \% \text{ MP} + 6.20000\text{E-}003 \text{ TEM} * \% \text{ MP} - 0.15385 \text{ pH}^2 - \\ & 2.38547\text{E-}003 \text{ TEM}^2 + 4.25953\text{E-}003 \% \text{ MP}^2 \end{aligned}$$

3D and Contour graph for retention time: From ANOVA report on retention time of pibrentasvir clearly states that

Fig. 4. (a) Contour plots and (b) response surface for retention time of glecaprevir as a function of pH of mobile phase and % mobile phase ratio (constant temperature 30 °C)

Source	Sum of squares	df	Mean square	F-value	p-value	
Model	24.68433	9	2.742704	35.00541	< 0.0001	Significant
A-pH	0.167167	1	0.167167	2.133571	0.1748	
B-TEM	0.108418	1	0.108418	1.383755	0.2667	
C-%MP	20.90503	1	20.90503	266.813	< 0.0001	
AB	0.167621	1	0.167621	2.139358	0.1743	
AC	0.201613	1	0.201613	2.573201	0.1398	
BC	0.276768	1	0.276768	3.532418	0.0896	
A ²	0.0819	1	0.0819	1.045304	0.3307	
B ²	0.006643	1	0.006643	0.08478	0.7769	
C ²	2.614721	1	2.614721	33.37195	0.0002	
Residual	0.783509	10	0.078351			
Lack of Fit	0.643127	5	0.128625	4.581281	0.0602	Not significant
Pure Error	0.140382	5	0.028076			
Cor Total	25.46784	19				
Summary of quadratic model						
Std. Dev.	0.28	PRESS	5.37	Adequate precision	22.652	
R ²	0.9692	Adjusted R ²	0.9415	Predicted R ²	0.7892	

interaction effect of pH and temperature has p-value higher than 0.05 so interaction effect these terms doesn't have any significant effect on retention time of pibrentasvir. The interaction effect temperature and % mobile phase p-value also greater than 0.05, also don't have any significant effect on resolution. The interaction effect of pH of mobile phase and % mobile phase ratio has little significant effect on retention time of pibrentasvir. By keeping constant temperature at 30 °C, the interaction effect of pH of mobile phase and % mobile phase ratio were studied from contour and 3D graph (Fig. 5). Lower than 65 % mobile phase ratio at given temperature range gives low retention time of pibrentasvir. Above 65 % to 75 % of mobile phase ratio and 30 to 33 °C of column temperature give the retention time of pibrentasvir above 4.0 to 4.9 min.

Method optimization through DoE software: The accuracy of the model was evaluated by numerical optimization

method by the design expert software. The desired goals for method response resolution was kept at maximum 3.1 and retention time of glecaprevir (2.028-3.569 min) and pibrentasvir (2.465-7.114 min) were kept in range. The chromatographic conditions suggested by design expert were pH 4.85, temperature at 28 °C and % mobile phase ratio at 73.15 with desirability 1. At these conditions the predicted method responses calculated by the model for resolution was 3.11, retention time of glecaprevir was 2.922 min and retention time of pibrentasvir was at 4.8909 min. The same experimental conditions were maintained and run the HPLC system. The optimized chromatogram of alkali degraded glecaprevir and pibrentasvir were obtained and it produced satisfactory system suitability parameters. This revealed that all the responses were within the statistical limit of 95 % confidence intervals leading to high degree of closeness of the predicted data with the observed ones.

Fig. 5. Contour plots (a) and response surface (b) for retention time of pibrentasvir as a function of temperature and % mobile phase ratio (constant pH of mobile phase 4.20)

TABLE-8
VERIFICATION OF EXPERIMENT AT OPTIMUM CONDITIONS

Method response	Prediction	95 % CI low	95 % CI high	Observed
Resolution	3.119	2.66	3.58	3.100
Retention time of glecaprevir	2.92	2.75	3.09	2.936
Retention time of pibrentasvir	4.89	4.52	5.26	4.889

The verification data of predicted values by the model and observed values were given in the Table-8.

Conclusion

A simple, selective and robust stability indicating RP-HPLC method was developed for the estimation of glecaprevir and pibrentasvir in bulk drug through the application of quality by design approach. QbD approach helps us to understand the influencing parameters and its effect on method responses along with risk assessment. Interaction among all the variables was investigated by employing response surface full factorial central composite design. The significant effects of individual factor, interaction effect between the variables on individual method responses were studied. The optimal setting of chromatographic conditions was in the analytical design space using desirability function was obtained. The demonstrated high predictability model can use for the estimation of glecaprevir and pibrentasvir routine analysis.

ACKNOWLEDGEMENTS

One of the authors (C. Vanitha) thanks Sri Venkateswara College of Pharmacy, RVS Nagar, Chittoor, India for providing research facilities for completion of this research work.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

- H. Hubbard and E. Lawitz, *Expert Rev. Gastroenterol. Hepatol.*, **12**, 9 (2018); <https://doi.org/10.1080/17474124.2018.1411802>.
- P.Y. Kwo, F. Poordad, A. Asatryan, S. Wang, D.L. Wyles, T. Hassanein, F. Felizarta, M.S. Sulkowski, E. Gane, B. Maliakkal, J.S. Overcash, S.C. Gordon, A.J. Muir, H. Aguilar, K. Agarwal, G.J. Dore, C.-W. Lin, R. Liu, S.S. Lovell, T.I. Ng, J. Kort and F.J. Mensa, *J. Hepatol.*, **67**, 263 (2017); <https://doi.org/10.1016/j.jhep.2017.03.039>.
- D.C. Babu, C.M. Chetty and M. SK. Mastanamma, *Pharm. Methods*, **9**, 79 (2018); <https://doi.org/10.5530/phm.2018.2.14>.
- Md. Abdul Sattar and A. Suneetha, *Int. J. Res. Pharm. Life Sci.*, **6**, 25 (2018).
- K. Hemalatha, C. Kistayya, N.D. Nizamuddin and D. Dastiagiramma, *Innovat. Int. J. Med.Pharm. Sci.*, **3**, 5 (2018).
- M. Sridevia, T.S. Rao and C.G. Naidu, *Eur. J. Biomed. Pharm. Sci.*, **5**, 473 (2018).
- Y.N. Reddy, J. Sreeramulu and B. Balaswami, *Res. J. Pharm. Technol.*, **12**, 625 (2019); <https://doi.org/10.5958/0974-360X.2019.00111.2>.
- V. Sreeram and Ch. Venkateswarlu, *J. Pharm. Sci. Res.*, **10**, 2757 (2018).
- ICH Q8 Quality Guidance: Pharmaceutical Development.
- S. Beg, G. Sharma, O.P. Katare, S. Lohan and B. Singh, *J. Chromatogr. Sci.*, **53**, 1048 (2015); <https://doi.org/10.1093/chromsci/bmv165>.
- N.K. Yadav, A. Raghuvanshi, G. Sharma, S. Beg, O.P. Katare and S. Nanda, *J. Chromatogr. Sci.*, **54**, 377 (2016); <https://doi.org/10.1093/chromsci/bmv151>.
- ICH Guideline, Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization: Geneva, Switzerland (2005).
- ICH Guideline, Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization: Geneva, Switzerland (2003).